A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.

Ozge GumusayLaura A HuppertMark Jesus M MagbanuaChiara A WablMichael AssefaAmy Jo ChienMichelle E MeliskoMelanie C MajureMark MoasserJohn ParkHope S Rugo

Published in: Breast cancer research and treatment (2023)

In heavily pretreated patients with ABC, treatment with EC resulted in an encouraging CBR of 79.5% and PFS of 16.4 weeks, which compares favorably to single-agent eribulin. Dose reduction and delays were primarily due to neutropenia. The contribution of cyclophosphamide to eribulin remains unclear but warrants further evaluation. NCT01554371.

Keyphrases

metastatic breast cancer
phase ii
high dose
low dose
clinical trial
randomized controlled trial
open label
young adults
preterm birth
phase iii
smoking cessation